Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients

Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma

(2011) A. De Luisi et al.   CLINICAL CANCER RESEARCH

Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma

(2011) E. P. Diamandis et al.   CLINICAL CANCER RESEARCH

High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients

(2011) M. Vanska et al.   HAEMATOLOGICA

FGF-dependent regulation of VEGF receptor 2 expression in mice

(2011) Masahiro Murakami et al.   JOURNAL OF CLINICAL INVESTIGATION

The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells

(2011) Kathleen E. Lambert et al.   MOLECULAR BIOLOGY OF THE CELL

Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets

(2011) S Berardi et al.   ONCOGENE

bFGF Regulates PI3-Kinase-Rac1-JNK Pathway and Promotes Fibroblast Migration in Wound Healing

(2010) Shigeyuki Kanazawa et al.   PLoS One

Emerging therapies for multiple myeloma

(2009) Klaus Podar et al.   EXPERT OPINION ON EMERGING DRUGS

Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide

(2009) Daria Leali et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

FGF2 stimulates SDF-1 expression through theErmtranscription factor in Sertoli cells

(2009) Kyung-Ae Yoon et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

The FGF system has a key role in regulating vascular integrity

(2008) Masahiro Murakami et al.   JOURNAL OF CLINICAL INVESTIGATION